MoneyHero stock initiated with Buy rating at Greenridge Capital

Greenridge Capital initiated coverage on MoneyHero Ltd. (MNY) with a Buy rating and a $4.00 price target, a substantial premium to its current $1.05 trading price and recent 49% weekly gain. The firm cites significant revenue and profit potential from MNY's high-margin insurance brokerage and potential market expansion, believing the market currently undervalues the company's strategic positioning. Greenridge's valuation, based on 2026 revenue and EBITDA estimates, aligns MNY with its peers, suggesting a potential re-rating as the company reports strong future financial results.

Analysis

Greenridge Capital has initiated coverage on MoneyHero Ltd. (MNY) with a Buy rating and a $4.00 price target, representing a significant premium to its current $1.05 trading price, even after the stock's recent 49% gain in the past week. The firm's bullish thesis is centered on the potential for substantial revenue and profit growth driven by the expansion of MNY's high-margin insurance brokerage business and potential inorganic growth through acquisitions in neighboring markets. Greenridge's valuation is based on long-term 2026 estimates, using an enterprise value-to-revenue multiple of 1.25x on projected revenue of $118.0 million and a 10x enterprise value-to-EBITDA multiple on projected adjusted EBITDA of $12.6 million. The core of the investment argument is that the market has overlooked management's strategic positioning, with the expectation that strong financial results in upcoming quarters will act as a catalyst for a stock re-rating to valuation multiples that are in line with its peers.

Key Decisions for Investors

• Given the substantial upside between the current $1.05 price and the $4.00 analyst target, investors with a higher risk tolerance could view this as a speculative opportunity, contingent on the company's future execution.
• It is critical to monitor MoneyHero's upcoming quarterly financial reports for tangible evidence of revenue growth and margin improvement from its insurance segment, as this is the primary catalyst cited for the stock's potential re-rating.
• Investors should recognize the long-term nature of this thesis, as the valuation is based on 2026 estimates, which introduces significant execution risk and requires patience through potential market volatility.